Krishna Gorti - Medicines IR Contact Officer
Executive
Krishna Gorti is IR Contact Officer of The Medicines since 2016.
| Tenure | 8 years |
| Phone | 973 290-6000 |
| Web | www.themedicinescompany.com |
Medicines Management Efficiency
Medicines' management efficiency ratios could be used to measure how well Medicines manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 865 M in liabilities. Medicines has a current ratio of 0.75, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Medicines until it has trouble settling it off, either with new capital or with free cash flow. So, Medicines' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Medicines sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Medicines to invest in growth at high rates of return. When we think about Medicines' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Lee Sterling | Simon Property Group | N/A | |
| Jennifer Stoecklein | American Eagle Outfitters | N/A | |
| Philipp Barthold | MYT Netherlands Parent | N/A | |
| Devon Gago | Figs Inc | N/A | |
| Cassandra Powers | Olympic Steel | N/A | |
| Steven Fivel | Simon Property Group | 63 | |
| W Cole | Simon Property Group | N/A | |
| Marisa Baldwin | American Eagle Outfitters | 53 | |
| Sean Heenan | Olympic Steel | 43 | |
| Matthew Dennis | Olympic Steel | N/A | |
| Bjorn Kastl | MYT Netherlands Parent | N/A | |
| Joseph Chiappetta | Simon Property Group | N/A | |
| Laura Porco | Ralph Lauren Corp | N/A | |
| Jean Fontana | Figs Inc | N/A | |
| Roseann Lynch | Ralph Lauren Corp | N/A | |
| Michelle SPHR | Olympic Steel | N/A | |
| Valeria Juarez | Ralph Lauren Corp | 51 | |
| Allan Churchmack | Arhaus Inc | N/A | |
| Alexander Snyder | Simon Property Group | 51 | |
| Russell Tuttle | Simon Property Group | N/A | |
| Sherry Harris | American Eagle Outfitters | N/A | |
Management Performance
| Return On Equity | -10970.3 | |||
| Return On Asset | -0.0017 |
Medicines Leadership Team
Elected by the shareholders, the Medicines' board of directors comprises two types of representatives: Medicines inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Medicines. The board's role is to monitor Medicines' management team and ensure that shareholders' interests are well served. Medicines' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Medicines' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Melvin Spigelman, Independent Director | ||
| Christopher Visioli, CFO, Treasurer | ||
| Armin Kessler, Independent Director | ||
| Fredric Eshelman, Non-Executive Chairman of the Board | ||
| Christopher Cox, Executive Vice President chief corporate development officer | ||
| Krishna Gorti, IR Contact Officer | ||
| Geno Germano, Independent Director | ||
| Stephen Rodin, Senior Vice President General Counsel, Secretary | ||
| William Crouse, Independent Director | ||
| Robert Savage, Independent Director | ||
| Stuart Kingsley, President COO | ||
| Alexander Denner, Director | ||
| Robert Hugin, Independent Director | ||
| John Kelly, Independent Director | ||
| Elizabeth Wyatt, Lead Independent Director | ||
| Hiroaki Shigeta, Independent Director | ||
| Mark Timney, CEO, Director | ||
| Tony Kingsley, President COO | ||
| Sarah Schlesinger, Independent Director | ||
| Clive Meanwell, Chairman of the Board, CEO | ||
| Jeffrey Frazier, Executive Vice President Chief Human Strategy Officer | ||
| Paris Panayiotopoulos, Director | ||
| William OConnor, CFO |
Medicines Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Medicines a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -10970.3 | |||
| Return On Asset | -0.0017 | |||
| Profit Margin | (0.0001) % | |||
| Operating Margin | (58.54) % | |||
| Current Valuation | 7.33 B | |||
| Shares Outstanding | 79.93 M | |||
| Shares Owned By Insiders | 4.22 % | |||
| Shares Owned By Institutions | 95.78 % | |||
| Number Of Shares Shorted | 25.18 M | |||
| Price To Earning | (3.24) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Medicines in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Medicines' short interest history, or implied volatility extrapolated from Medicines options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Medicines information on this page should be used as a complementary analysis to other Medicines' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Other Consideration for investing in Medicines Stock
If you are still planning to invest in Medicines check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Medicines' history and understand the potential risks before investing.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stocks Directory Find actively traded stocks across global markets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |